Company	Investors	Use Of Proceeds
Corvus Pharmaceuticals; Burlingame, California	In a Form D filed with the SEC on Sept. 25, the company indicated that it's raised nearly $75m with support from Adams Street Partners LLC, Novo A/S and OrbiMed Advisors LLC. Corvus previously raised $33.5m in Series A venture capital from the same three investors.	The former founding CEO of Pharmacyclics Inc., which AbbVie acquired for $21bn this year, is leading Corvus's development of immuno-oncology drugs and antibodies. A Phase Ib clinical trial for the company's first checkpoint inhibitor is expected to begin in early 2016.
Alector LLC; San Francisco	MRL Ventures led Alector's $32m Series C round with participation from OrbiMed, Polaris Partners, Google Ventures, Topspin Partners, Mission Bay Capital and other investors. The company raised $10m in Series A cash in October 2013 and entered into an Alzheimer's disease collaboration with Johnson & Johnson in March 2014.	Alector is developing immuno-modulatory antibody therapies for Alzheimer's disease and other neurodegenerative disorders, with the goal of "harnessing the immune system to fight multiple aspects of these disorders," according to co-founder, president and CEO Arnon Rosenthal. The company will use the new funding to broaden its pipeline and advance therapeutic candidates toward clinical trials.
Replimune Ltd.; Oxford, UK	Atlas Venture led a $30m Series A round for Replimune with participation from the company's previous investors Forbion Capital Partners and Omega Funds. The UK-based company also operates from a site in Cambridge, Massachusetts.	Replimune is developing next-generation immunotherapies that use oncolytic viruses to selectively replicate and kill tumors while inducing an immune response. The new funding will support clinical trials, including the pursuit of partnerships to test the company's technology in combination with other immuno-oncology drugs.
Akari Therapeutics; New York	Deerfield Management Co. led a $75m private placement to finance Akari, a public company that was created through the merger of Celsus Therapeutics Plc and Volution Immuno Pharmaceuticals SA. Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management and other unnamed institutional investors also participated in the financing, which values Akari at $150m.	The capital will fund development of Coversin, a second-generation complement inhibitor that acts on complement component-C5, preventing release of C5a and formation of C5b-9, for the treatment of autoimmune and rare diseases, such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and Guillain Barré syndrome (GBS).
ImmunoCellular Therapeutics Ltd.; Los Angeles	The California Institute of Regenerative Medicine (CIRM), which is in the middle of updating its strategic plan and launched CIRM 2.0 to improve access to funding for commercial stem cell-based therapies, provided a $19.9m grant to help fund a Phase III clinical trial for ITC-107 in the treatment of newly-diagnosed glioblastoma.	ITC-107 is an immunotherapy that preferentially targets and kills cancer stem cells with the goal of preventing tumor recurrence following treatment with the standard of care. ImmunoCellular plans to initiate a 400-patient Phase III trial in the fourth quarter of 2015. The CIRM grant plus the company's cash on hand will fund the entire study. ITC-107 failed in Phase II, but ImmunoCellular is moving forward with a registrational study in HLA-A2-positive brain cancer patients under a special protocol assessment (SPA) agreed to by the US FDA.

FINANCE ROUNDUP: Will VC Be Last Man Standing If Biotech Bubble Bursts?

More from Anti-infective

More from Therapeutic Category